Inside This MedTech Company’s Turnaround: Can Its Stock Double? [GeoWire Weekly No. 159]

Welcome to The GeoWire , your source for a Peek into GeoInvesting’s Research Coverage, Microcap Stock Education, Case Studies, Featured Videos, and More. Please share this if you like today’s newsletter and comment with any feedback.

---

If you are new or this was shared with you, you can join our email list here.

For real time analysis of our coverage universe, including new high conviction ideas and additions to our model portfolios, if you are not already a premium subscriber, consider supporting our movement by becoming a premium member today. GeoInvesting, 16 years and counting!

Highlights This Med-tech company’s turnaround is driven by operational restructuring, a focus on higher-margin U.S. markets, and a patient-first approach under its new CEO. The company has reported two consecutive quarters of profitability, with strong revenue growth and flat operating expenses. We expect a near-term upside of at least 100%. Key catalysts include continued sales and EPS growth, as well as the divestiture of part of the business. The CEO says the company is taking market share “like crazy” in its operating space He adds, “We’ve built a model that scales well. We’ve bottomed out on operating expenses and are now poised to make investments that will fuel the next phase of growth, without eroding profitability.”

Growth Has Begun As Restructuring Inflects

This company develops and sells advanced med-tech products, primarily for hospitals, healthcare facilities.

We believe the company is at a pivotal point in its 20-year history and is entering a period of more predictable growth. 

Our analysis indicates that the stock is poised for at least 100% increase in price in the near term.

Challenges faced in recent years culminated in a string of eight consecutive quarterly losses. However, a series of decisions, led by a new CEO, has set the stage for what could be a significant turnaround. He joined the company in 2024 to lead a turnaround that had begun under prior management.

The company’s return to profitability in Q2 2024 was followed by another strong quarter in Q3 2024, strengthening our confidence in its growth prospects. 

With its emphasis on accelerating the growth of higher-margin products in the United States and a patient-driven focus on advanced wound care and infection control, the company appears well-positioned to sustain its momentum.

 

The remainder of this post is only visible to paid subscribers of GeoInvesting. To access our expanded coverage on Select Microcap stocks & More, Subscribe below.

Please don’t forget to consider supporting GeoInvesting with a premium subscription if you enjoyed this content, and want to see more of it. Complete this short survey to let us know you’re engaged and interested.

SIGN IN

200+ multibaggers and counting

 

---

GeoInvesting is a premier research platform for microcap investors, dedicated to uncovering high-potential stock ideas in undervalued companies across various sectors. With over 30 years of investing experience, GeoInvesting has covered more than 1,500 equities, providing often actionable proprietary research. The platform has been instrumental in identifying 200+ multibagger stocks, and offers investors exclusive access to over 600 management interview clips, allowing for deeper due diligence and understanding of the microcap stocks, many of which make it to market-beating premium Model Portfolios. Join the GeoInvesting community for the best stock research and microcap insights to help you stay ahead in the market. To learn more about our Premium Services, go here.. (https://geoinvesting.com/premium-research/)

The post Inside This MedTech Company’s Turnaround: Can Its Stock Double? [GeoWire Weekly No. 159] appeared first on GeoInvesting.

Source: https://geoinvesting.com/inside-this-medtech-companys-turnaround-can-its-stock-double/